Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation

Journal of Pharmaceutical Sciences

Volumn 95, Issue 5, 2006, Pages 1084-1096

  Hermeling, Suzanne ^a,b   Schellekens, Huub ^b   Maas, Coen ^c   Gebbink, Martijn F B G ^c   Crommelin, Daan J A ^a   Jiskoot, Wim ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Immune tolerant; Immunology; Interferon alpha2b; Protein aggregation; Protein structure; Proteins; Transgenic mice

Indexed keywords

ALPHA2B INTERFERON; METAL; RECOMBINANT ALPHA INTERFERON;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE SPECTROSCOPY; GEL PERMEATION CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LIGHT SCATTERING; MOUSE; NONHUMAN; OXIDATION; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN CONFORMATION; TEMPERATURE; TRANSGENIC MOUSE; ULTRAVIOLET SPECTROSCOPY; WESTERN BLOTTING; WILD TYPE;

EID: 33646546740     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20599     Document Type: Note

References (33)

1. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897-903.
2. Schellekens H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457-462.
3. Schernthaner G. 1993. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16:155-165.
4. Palleroni AV, Aglione A, Labow M, Brunda MJ, Pestka S, Sinigaglia F, Garotta G, Alsenz J, Braun A. 1997. Interferon immunogenicity: Preclinical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 17:S23-27.
5. Hochuli E. 1997. Interferon immunogenicity: Technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 17:S15-21.
6. Ryff JC. 1997. Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res 17:S29-33.
7. Moore WV, Leppert P. 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51:691-697.
8. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S. 1998. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58:2489-2499.
9. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14:1472-1478.
10. Hermeling S, Aranha L, Damen JMA, Slijper M, Schellekens H, Crommelin DJA, Jiskoot W. 2005. Structural characterization and immunogenicity in wildtype and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 22:1997-2006.
11. Da Silva DM, Schiller JT, Kast WM. 2003. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 21:3219-3227.
12. Chackerian B, Lowy DR, Schiller JT. 2001. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108:415-423.
13. Chackerian B, Lenz P, Lowy DR, Schiller JT. 2002. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169:6120-6126.
14. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. 1993. The influence of antigen organization on B cell responsiveness. Science 262:1448-1451.
15. Ruiz L, Reyes N, Duany L, Franco A, Aroche K, Hardy Rando E. 2003. Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin. Int J Pharm 264:57-72.
16. Peterson GL. 1977. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83:346-356.
17. Kumar V, Sharma VK, Kalonia DS. 2005. Second derivative tryptophan fluorescence spectroscopy as a tool to characterize partially unfolded intermediates of proteins. Int J Pharm 294:193-199.
18. Savitzky A, Golay MJE. 1964. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem 36:1627-1639.
19. Kueltzo LA, Midddaugh CR. 2005. Ultraviolet Absorption spectroscopy. In: Jiskoot W, Crommelin DJA, editors. Methods for structural analysis of protein pharmaceuticals, ed., Arlington: AAPS Press. p 1-25.
20. Sharma VK, Kalonia DS. 2003. Temperature- and pH-induced multiple partially unfolded states of recombinant human interferon-alpha2a: Possible implications in protein stability. Pharm Res 20:1721-1729.
21. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129-188.
22. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in non-native protein aggregation. Pharm Res 20:1325-1336.
23. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein pharmaceuticals. Pharm Res 6:903-918.
24. Sebeka HK, Starkuviene B, Trepsiene OV, Pauliukonis AA, Bumelis VA. 2001. Comparative effects of stabilizing additives on the rates of heat inactivation of recombinant human interferon alpha-2b in solution. Antiviral Res 50:117-127.
25. Beldarrain A, Cruz Y, Cruz O, Navarro M, Gil M. 2001. Purification and conformational properties of a human interferon alpha2b produced in Escherichia coli. Biotechnol Appl Biochem 33:173-182.
26. Purvis AR, Sadler JE. 2004. A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization. J Biol Chem 279:49982-49988.
27. Powell MF. 1996. A compendium and hydropathy flexibilityanalysis of common reactive sites in proteins: Reactivity at Asn, Asp, Gln and Met motifsin neutral pH solution. In: Pearlman R, Wang YJ, editors. Formulation, characterization and stability of protein drugs, 1 ed., New York: Plenum press. p 1-81.
28. Robbins DC, Cooper SM, Fineberg SE, Mead PM. 1987. Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients. Diabetes 36:838-841.
29. Fehr T, Bachmann MF, Bucher E, Kalinke U, Di Padova FE, Lang AB, Hengartner H, Zinkernagel RM. 1997. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 185:1785-1792.
30. Bachmann MF, Hengartner H, Zinkernagel RM. 1995. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: Role of antigen patterns in B cell induction? Eur J Immunol 25:3445-3451.
31. Braun A, Alsenz J. 1997. Development and use of enzyme-linked immunosorbent assays (ELISA) for the detection of protein aggregates in interferon-alpha (IFN-alpha) formulations. Pharm Res 14:1394-1400.
32. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15:641-649.
33. Hermeling S, Jiskoot W, Crommelin DJA, Bornaes C, Schellekens H. 2005. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm Res 22:847-851.